Eton Pharmaceuticals Awarded US Patent for Proprietary Hydrocortisone Oral Liquid Formulation

Eton Pharmaceuticals recently announced the United States Patent and Trademark Office (USPTO) has granted the company’s US Patent Application No. 18/113,458, which covers the company’s ET-400 product candidate’s proprietary formulation of oral liquid hydrocortisone. The patent has an expiration in 2043 and is expected to be listed in the FDA’s Orange Book upon the product’s approval. The company has additional patent applications related to the product under review with the USPTO.

Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company currently has four FDA-approved rare disease products, ALKINDI SPRINKLE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector. For more information, visit